YDES
YD BioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About YDES
Yd Bio Limited
A biopharmaceutical company specializing in blood based cancer detection
Biological Technology
02/06/2024
08/29/2025
NASDAQ Stock Exchange
4
12-31
--
Common stock
12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan
--
YD Bio Limited was incorporated in the Cayman Islands on February 6, 2024. They are a biopharmaceutical company that focuses on blood-based cancer detection, develops stem cell and exosome-based therapies, has the potential to transform the treatment of broad-spectrum diseases with high unmet medical needs, and serves as a trusted supplier of clinical laboratory drugs for pharmaceutical companies. Their business model focuses on developing partnerships with biopharmaceutical companies to turn innovative technologies into commercially viable drugs and cancer detection.
Company Financials
EPS
YDES has released its 2022 Q1 earnings. EPS was reported at 0.18, versus the expected 0, beating expectations. The chart below visualizes how YDES has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
